ZLABZai Lab Ltd
$17.91
$0.835
(4.89%)
EarningsAug 6
Mkt Cap$1.92B
Vol131,928.00
Fundamentals
Mkt Cap
$1.92B
Volume
-
52W High
$41.20
52W Low
$15.96
PE Ratio
-10.53
Avg. Volume
779,966.84
EPS (Annual)
-$1.61
Rev/Employee
$258,617.15
Earnings
Aug 06
Zai Lab Receives China NMPA Approval of TIVDAK (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that Chinas National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer...
Business Wire
Zai Lab Announces Changes to Senior Leadership Team
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made the decision that Josh Smiley, President and COO, will no longer be with the Company...
Business Wire
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to zocilurtatug pelitecan (zoci, formerly ZL-1310), the...
Business Wire
Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Zai Lab Limited (ZLAB) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2026, along with recent product highlights and corporate updates. We continue to accelerate the...
Business Wire
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight brokerages that are presently covering the firm...
MarketBeat
Zai Lab Showcases 54% Brain Metastases Response for ZL-1310 ADC in SCLC at AACR Investor Call
Zai Lab (NASDAQ:ZLAB) hosted an investor call tied to the 2026 American Association for Cancer Research (AACR) meeting to highlight new data for its DLL3-targeted antibody-drug conjugate (ADC...
MarketBeat
Zai Lab (NASDAQ:ZLAB) Trading Down 5.2% - Here's What Happened
Zai Lab (NASDAQ:ZLAB) Shares Down 5.2% - What's Next...
MarketBeat
Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its first quarter 2026 financial results and provide recent corporate updates on May 7, 2026, before the opening of U.S...
Business Wire
Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31R Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced new data from a preclinical study of ZL-1503, demonstrating that the companys internally developed IL-13/IL-31R bispecific antibody may lead...
Business Wire
<
1
2
...
>
Advertisement|Remove ads.
Latest ZLAB News
ViewZai Lab Receives China NMPA Approval of TIVDAK (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
Business Wire
Zai Lab Announces Changes to Senior Leadership Team
Business Wire
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
Business Wire
Advertisement|Remove ads.